Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eurand has completed a gastrointestinal bioavailability study on Zentase, its lead product candidate for the treatment of exocrine pancreatic insufficiency. The study was conducted in chronic pancreatitis patients in the US.
Subscribe to our email newsletter
Results from the study will be included in Eurand’s new drug application (NDA) for Zentase. Eurand initiated its rolling NDA submission in June 2007 and has been granted Fast Track designation by the FDA.
Gearoid Faherty, CEO, said: “The completion of this study will allow us to complete our NDA submission for Zentase before the end of the year as planned.”